ADVANCED-1/ IGUB21083 / Messing
Research Question:
not to be listed
Basic Study Information
Purpose:
This study is an open-label dose escalation study (Phase 1a) to investigate the safety
and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including
CIS with concomitant Ta) after transurethral resection of bladder tumor (TURBT) and/or
biopsy using TARA-002 in adults unable to obtain intravesical Bacillus Calmette-Guérin
(BCG), adults who have received at least one dose of intravesical BCG or adults who
have received at least one dose of intravesical chemotherapy. Dosing will start in
subjects with HGTa or CIS (including CIS with concomitant Ta), and all subjects will
receive 6 weeks of treatment at a fixed volume with varying dose levels.
Location: University of Rochester, Department of Urology
Lead Researcher (Principal Investigator)
Lead Researcher:
Edward Messing
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search